Preclinical studies demonstrated that treatment of tumor-bearing hosts with OX40 agonists, including both anti-OX40 mAb and OX40L-Fc fusion proteins, resulted in tumor regression in several preclinical models (20, 26, 27, 38–40). The gene discussed is TNFRSF4; the disease is neoplasm.